Gabriela Baerlocher

Prof. Dr. Gabriela Baerlocher


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2006 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
GBGabriela Baerlocher
Gabriela Baerlocher
IVIrma Vulto
Irma Vulto
GJGary de Jong
Gary de Jong
PLPeter M Lansdorp
Peter M Lansdorp

3 September 2015 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GBGabriela Baerlocher
Gabriela Baerlocher
ELElisabeth Oppliger Leibundgut
Elisabeth Oppliger Leibundgut
OOOliver G. Ottmann
Oliver G. Ottmann
GSGary Spitzer
Gary Spitzer
OOOlatoyosi Odenike
Olatoyosi Odenike
DSDavid S. Snyder
David S. Snyder
Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients with essential thrombocythemia. In this phase 2 study, we investigated whether imetelstat could elicit hematologic and molecular responses in patients with essential thrombocythemia who had not had a response to or who had had unacceptable side effects from prior therapies.

31 March 2010 in Leukemia Research
Verified
Journal Article
Closed access
Mario P. TschanMario P. Tschan
Mario P. Tschan
DSDeborah Shan
Deborah Shan
JLJudith Laedrach
Judith Laedrach
MEMarianne Eyholzer
Marianne Eyholzer
ELElisabeth Oppliger Leibundgut
Elisabeth Oppliger Leibundgut
MFMartin F. Fey
Martin F. Fey

2 July 2009 in Blood
Verified
Journal Article
Open access
PDF file
GBGabriela Baerlocher
Gabriela Baerlocher
ARAlicia Rovó
Alicia Rovó
AMAstrid Müller
Astrid Müller
SMSybille Matthey
Sybille Matthey
MSMartin Stern
Martin Stern
ATAndré Tichelli
André Tichelli
In this single-center, cross-sectional study, we evaluated 44 very long-term survivors with a median follow-up of 17.5 years (range, 11-26 years) after hematopoietic stem cell transplantation. We assessed the telomere length difference in human leukocyte antigen-identical donor and recipient sibling pairs and searched for its relationship with clinical factors. The telomere length (in kb, mean ± SD) was significantly shorter in all recipient blood cells compared with their donors' blood cells (P < .01): granulocytes (6.5 ± 0.9 vs 7.1 ± 0.9), naive/memory T cells (5.7 ± 1.2 vs 6.6 ± 1.2; 5.2 ± 1.0 vs 5.7 ± 0.9), B cells (7.1 ± 1.1 vs 7.8 ± 1.1), and natural killer/natural killer T cells (4.8 ± 1.0 vs 5.6 ± 1.3). Chronic graft-versus-host disease (P < .04) and a female donor (P < .04) were associated with a greater difference in telomere length between donor and recipient. Critically short telomeres have been described in degenerative diseases and secondary malignancies. If this hypothesis can be confirmed, identification of recipients at risk for cellular senescence could become part of monitoring long-term survivors after hematopoietic stem cell transplantation.

27 September 2007 in Leukemia
Verified
Journal Article
Closed access
ARA Röth
A Röth
JDJ Dürig
J Dürig
HHH Himmelreich
H Himmelreich
SBS Bug
S Bug
RSR Siebert
R Siebert
GBGabriela Baerlocher
Gabriela Baerlocher

29 August 2023 in Science Signaling
Verified
Journal Article
Closed access
PNPascal Naef
Pascal Naef
RRRamin Ramin Radpour
Ramin Ramin Radpour
CJCarla A. Jaeger-Ruckstuhl
Carla A. Jaeger-Ruckstuhl
NBNils Bodmer
Nils Bodmer
GBGabriela Baerlocher
Gabriela Baerlocher
AOAdrian F. Ochsenbein
Adrian F. Ochsenbein
Cell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia cells in a subtype-specific manner. The IL-33 receptor ST2 was abundant on the surfaces of CD34 + BCR/ABL1 CML and CD34 + AML cells harboring AML1/ETO and DEK/NUP214 translocations or deletion of chromosome 9q [del(9q)]. The cell surface abundance of ST2, which was lower or absent on other leukemia subtypes and HSCs, correlated with stemness, activated Wnt signaling, and repressed Notch signaling. IL-33–ST2 signaling promoted the maintenance and expansion of AML1/ETO–, DEK/NUP214–, and BCR/ABL1–positive LSCs in culture and in mice by activating Wnt, MAPK, and NF-κB signaling. Wnt signaling and its inhibition of the Notch pathway up-regulated the expression of the gene encoding ST2, thus forming a cell-autonomous loop. IL-33–ST2 signaling promoted the resistance of CML cells to the tyrosine kinase inhibitor (TKI) nilotinib and of AML cells to standard chemotherapy. Thus, inhibiting IL-33–ST2 signaling may target LSCs to overcome resistance to chemotherapy or TKIs in these subtypes of leukemia.